Late Breaker: On Aug 3, the CDC director approved the ACIP’s recommendations that all infants < 8 months old born during or entering their first Respiratory Syncytial Virus (RSV) season receive one dose of nirsevimab. Additionally, children 8-19 months who are at increased risk of severe RSV disease should receive one dose of nirsevimab when entering their second RSV season. Nirsevimab is a long-acting monoclonal antibody targeting the pre-fusion F protein of RSV that was shown in clinical trials to have approximately 80% efficacy at reducing medically attending RSV visits and hospitalizations. Importantly, nirsevimab will be covered under the Vaccines for Children (VFC) program. This is a landmark decision and a huge step forward for pediatric health with the capacity to change the landscape of severe RSV disease in our youngest patients.